| Literature DB >> 21554992 |
M C Donohue1, A C Gamst, R G Thomas, R Xu, L Beckett, R C Petersen, M W Weiner, P Aisen.
Abstract
Randomized, placebo-controlled trials often use time-to-event as the primary endpoint, even when a continuous measure of disease severity is available. We compare the power to detect a treatment effect using either rate of change, as estimated by linear models of longitudinal continuous data, or time-to-event estimated by Cox proportional hazards models. We propose an analytic inflation factor for comparing the two types of analyses assuming that the time-to-event can be expressed as a time-to-threshold of the continuous measure. We conduct simulations based on a publicly available Alzheimer's disease data set in which the time-to-event is algorithmically defined based on a battery of assessments. A Cox proportional hazards model of the time-to-event endpoint is compared to a linear model of a single assessment from the battery. The simulations also explore the impact of baseline covariates in either analysis.Entities:
Mesh:
Year: 2011 PMID: 21554992 PMCID: PMC3148349 DOI: 10.1016/j.cct.2011.04.007
Source DB: PubMed Journal: Contemp Clin Trials ISSN: 1551-7144 Impact factor: 2.226